Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1738 PET/CT in Prostate Cancer
NCT07056439Phase 2Not yet recruiting
- Sponsor
- Hengrui
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-1738 in prostate cancer (PCa), sponsored by Hengrui. Primary endpoints: Adverse events (AEs) at 1 year and Serious adverse events (SAEs) at 1 year. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
HRS-1738
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07056439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07056439.